Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Destabilization of Microtubules01:45

Destabilization of Microtubules

2.8K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Mapping of the <i>TtGL-2A</i> Long-Grain Locus in Tetraploid Wheat.

Plants (Basel, Switzerland)·2026
Same author

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same author

Ultramutagenesis through combined Msh2 depletion and proofreading-deficient DNA polymerase ε expression enhances small molecule target identification in forward genetic screens.

bioRxiv : the preprint server for biology·2026
Same author

Loss of heterozygosity exposes germline mutations in complex I and drives Warburg metabolism in oncocytic carcinoma of the thyroid.

Science advances·2026
Same author

Multiscale photoacoustic imaging of stroke in preclinical models and future directions toward clinical translation [Invited].

Biomedical optics express·2026
Same author

The gut microbiota directs vitamin A flux to regulate intestinal T cell development.

Cell host & microbe·2026

Related Experiment Video

Updated: Sep 5, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

TK216 targets microtubules in Ewing sarcoma cells.

Juan Manuel Povedano1, Vicky Li1, Katherine E Lake1

  • 1Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX 75390 USA; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390 USA.

Cell Chemical Biology
|July 8, 2022
PubMed
Summary

The small molecule TK216, investigated for Ewing sarcoma, destabilizes microtubules, explaining its anti-cancer effects beyond its intended target. This discovery clarifies its mechanism and potential clinical applications.

Keywords:
Ewing sarcomaONCT-216TK216YK-4-279microtubulestarget identification

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Related Experiment Videos

Last Updated: Sep 5, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ewing sarcoma (EWS) is a pediatric cancer driven by the EWSR1-FLI1 fusion protein.
  • TK216 is a novel inhibitor targeting EWSR1-FLI1, currently in Phase II clinical trials for EWS.
  • The precise mechanism of TK216's cytotoxicity, especially in non-EWSR1-FLI1 expressing cells, remained unclear.

Purpose of the Study:

  • To elucidate the unresolved mechanism of TK216's anti-cancer activity.
  • To identify genetic factors conferring resistance to TK216.
  • To understand the basis for TK216's synergy with vincristine.

Main Methods:

  • Utilized a forward-genetics screening platform with engineered hypermutation in EWS cell lines.
  • Identified mutations in TUBA1B (encoding ⍺-tubulin) associated with TK216 resistance.
  • Performed in vitro microtubule (MT) polymerization assays and cell-based chemical probe competition assays.

Main Results:

  • Discovered recurrent TUBA1B mutations conferring resistance to TK216.
  • Demonstrated that TK216 functions as a microtubule (MT) destabilizing agent.
  • Established the mechanism of TK216 cytotoxicity and its synergy with vincristine.

Conclusions:

  • TK216's primary mechanism involves microtubule destabilization, not solely EWSR1-FLI1 inhibition.
  • This finding explains TK216's efficacy in a broader range of cancers and its synergy with vincristine.
  • Recommends re-evaluation of ongoing clinical trials involving TK216 based on its clarified mechanism of action.